- Report
- May 2025
- 100 Pages
Global
From €5321EUR$5,950USD£4,615GBP
- Report
- April 2025
- 175 Pages
Global
From €4015EUR$4,490USD£3,483GBP
From €4427EUR$4,950USD£3,840GBP
- Report
- April 2025
- 175 Pages
Global
From €4015EUR$4,490USD£3,483GBP
- Report
- September 2025
- 250 Pages
Global
From €4015EUR$4,490USD£3,483GBP
- Report
- September 2025
- 250 Pages
Global
From €4015EUR$4,490USD£3,483GBP
- Report
- September 2025
- 250 Pages
Global
From €4015EUR$4,490USD£3,483GBP
- Report
- April 2025
- 250 Pages
Global
From €4015EUR$4,490USD£3,483GBP
- Report
- April 2025
- 200 Pages
Global
From €7110EUR$7,950USD£6,167GBP
- Report
- September 2025
- 250 Pages
Global
From €4015EUR$4,490USD£3,483GBP
- Report
- September 2025
- 250 Pages
Global
From €4015EUR$4,490USD£3,483GBP
- Report
- April 2025
- 182 Pages
Global
From €4024EUR$4,500USD£3,491GBP
- Report
- September 2025
- 112 Pages
Global
From €3500EUR$4,192USD£3,142GBP
- Report
- June 2025
- 290 Pages
Global
From €4467EUR$4,995USD£3,875GBP
- Report
- July 2025
- 155 Pages
North America
From €3085EUR$3,450USD£2,676GBP
- Report
- April 2024
- 318 Pages
Global
From €5191EUR$6,007USD£4,350GBP
- Report
- August 2024
- 100 Pages
Global
From €5321EUR$5,950USD£4,615GBP
- Report
- December 2022
- 150 Pages
Global
From €5321EUR$5,950USD£4,615GBP
- Report
- October 2022
- 270 Pages
Global
From €2683EUR$3,000USD£2,327GBP
€3354EUR$3,750USD£2,909GBP
- Report
- September 2022
- 232 Pages
Global
From €2504EUR$2,800USD£2,172GBP
€3130EUR$3,500USD£2,715GBP

Remicade is a biologic drug used to treat immune disorders such as Crohn's disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis. It is a monoclonal antibody that works by blocking the action of tumor necrosis factor (TNF), a protein that plays a role in inflammation. Remicade is administered intravenously and is usually given in a series of three infusions over a period of several weeks.
Remicade is a major player in the immune disorders drugs market, with a wide range of indications and a long track record of safety and efficacy. It is one of the most widely prescribed biologic drugs in the world, and is used by millions of patients.
Companies in the Remicade market include Johnson & Johnson, Merck, Pfizer, AbbVie, and Amgen. Show Less Read more